| Autor: |
Lankford C; Department of Pharmacy, Cleveland Clinic, Cleveland, OH., Dura J; Department of Pharmacy, Cleveland Clinic, Cleveland, OH., Tran A; Department of Pharmacy, Cleveland Clinic, Cleveland, OH., Lam SW; Department of Pharmacy, Cleveland Clinic, Cleveland, OH., Naelitz B; Lerner College of Medicine, Cleveland Clinic, Cleveland, OH., Willner M; Department of Pharmacy, Cleveland Clinic, Cleveland, OH., Geyer K; Department of Pharmacy, Cleveland Clinic, Cleveland, OH. |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of managed care & specialty pharmacy [J Manag Care Spec Pharm] 2021 Mar; Vol. 27 (3), pp. 379-384. |
| DOI: |
10.18553/jmcp.2021.27.3.379 |
| Abstrakt: |
BACKGROUND: Patients who are prescribed specialty medications require close monitoring, including assessment of laboratory parameters, toxicities, and adherence. Specialty pharmacies integrated within a health system are able to access records, assess therapy, and efficiently communicate with prescribers. OBJECTIVE: To analyze interventions made by clinical pharmacists within the Cleveland Clinic Specialty Pharmacy (CCSP) regarding cost avoidance for the health care system and improvements in patient safety. METHODS: This was a retrospective, observational study that analyzed pharmacist interventions regarding specialty hematology/oncology medications. Interventions were measured with pharmacist documentation within the electronic health record (EHR). The primary endpoint was the cost-avoidance effect of clinical pharmacist interventions resulting from pharmacist access to the EHR. Secondary endpoints included pharmacist interventions that led to additional ancillary or supportive care, time taken to perform interventions, total interventions according to new or refill status, and total interventions performed according to insurance subtype. RESULTS: 547 interventions were identified during the study period, with a total cost avoidance of $1,508,131. The intervention with the highest overall cost savings was discontinuation of therapy ($290,091). The highest cost savings, based on intervention type, was lack of follow-up ($30,892). The medication with the highest overall cost savings was abiraterone ($273,160). Gilteritinib was associated with the highest cost saving per intervention ($28,350). The indication with the highest overall cost savings was prostate cancer ($402,601), while cutaneous T-cell lymphoma had the highest cost savings per intervention ($25,424). CONCLUSIONS: CCSP pharmacist interventions led to significant overall cost savings to the health care system. Although not measured in this study, it is reasonable to expect that decreased medication use may also translate into less financial burden for patients, as well as for pharmacy benefit managers. Access to the EHR and integration within the health care system may have facilitated the cost savings. DISCLOSURES: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors have no conflicts of interest to disclose. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
